Karuna Therapeutics

• NCT06729970

  Phase 1, Completed, 133 people, 12 Dec 2024

• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

  Phase 3, Recruiting, 500 people, 13 Nov 2023

• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  Phase 3, Recruiting, 1,000 people, 8 Aug 2023

Sources: clinicaltrials.gov

• Posttraumatic Stress Disorder Epigenome-Wide Association Studies in the Million Veteran Program

  Consulting or advice, 8 Sept 2026

• Plasma proteomic Alzheimer's risk score: Biological age clock and pseudotime trajectory

  Consulting or advice, Board or leadership role, 1 Oct 2025

Sources: pubmed.ncbi.nlm.nih.gov